Hair loss treatment should target dermal white adipose tissue (DWAT) to restore hair follicles. Potential remedies include tocopherol (vitamin E), botox, rosiglitazone, niacin, kojyl cinnamate esters, and ADP355.
Hair loss therapies focusing on hair follicle sugar metabolism and aldose reductase. Potential treatments include magnesium supplements, avoiding high glycemic index foods, and antioxidants.
HairClone is offering a Dermal Papilla Cell Hair Multiplication procedure in Guatemala, raising questions about its effectiveness and regulatory reasons for the location. Users express skepticism and curiosity about the treatment's success and potential costs.
The conversation discusses a video about GT20029, a treatment for hair loss, and its comparison to KX826. Users express interest in the video's effectiveness and potential, and praise its informative content.
PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.
PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.
IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.
Mixing Nizoral and T-Gel in a 1:1 ratio and using it three times a week provided relief from persistent seborrheic dermatitis. This treatment is recommended for those with stubborn SD.
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
Balding scalps have more androgen receptors, leading to increased TGF-beta, which causes blood vessel loss and hair follicle miniaturization. Blocking androgen signaling and TGF-beta may help prevent hair loss.
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
The conversation is about using micro needling and PTD-DBM for hair loss treatment. The user applies PTD-DBM drops on weekdays and performs micro needling weekly.
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.
The user reports hair regrowth after three months using a daily oral capsule with Minoxidil, Finasteride, and Biotin, derma stamping twice a week, and alternating Nizoral and Mane Root Activator Shampoo, with no side effects except increased nasal hair growth. They observed significant progress on the crown and thickening of the hairline.
The conversation is about organizing hair regrowth results using a standard format in a single post for easier access. Treatments mentioned include oral minoxidil, oral finasteride, and dermarolling.
Human pluripotent stem cells have been used to create hair and skin, potentially offering a new solution for baldness. A user also mentioned starting finasteride but experiencing unexpected hair thinning.
The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.
The conversation discusses the difficulty of applying tretinoin 0.025% cream on the scalp and considers switching to a gel for easier application. It also mentions that a liquid solution, ideally combined with minoxidil, may be more effective for hair treatment.
AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.
The user is concerned about hair loss despite taking finasteride and has a hair transplant scheduled. They experience scalp itching and burning, which hasn't been relieved by various treatments, and another user suggests using ghk-cu & ahk-cu serum and Koshine kx-826/pyrilutamide for relief.
The conversation is about using vitamin C and Magnesium L-Threonate for hair growth by reducing DHT binding to dermal papilla cells. The original post about vitamin C's pH levels and sebum control was possibly removed by a moderator.
The potential hair regrowth benefits of ASC-J9, a synthetic modified version of curcumin that is said to be more effective than Minoxidil and Finasteride. Reports from users suggest good thickening and temple regrowth with topical use at 0.025% concentration.
The user is seeking alternative hair loss treatments due to side effects from finasteride and minoxidil. They are inquiring about the availability of gt20029 from u-lab.
The conversation discusses hair loss treatments, specifically the use of topical minoxidil and derma-stamping, with suggestions to add finasteride or dutasteride for better long-term results. Ketoconazole shampoo is also considered for scalp health.
A user's extreme regimen for hair loss, which includes taking oral and topical medications such as minoxidil, dutasteride, cyproterone acetate and bicalutamide, but still experiencing miniaturization. Suggestions were made to try other treatments such as RU58841 and Pyrilutamide, while also considering mental health treatment and advice on lookmaxxing.